For the three months ended September 30, 2026, QIAGEN N.V. reported net income of $105.7 million, or $0.51 per diluted share, compared to $130.0 million, or $0.60 per diluted share, in the prior-year period. Net sales increased 2.9% to $547.9 million from $532.6 million. Gross profit rose to $354.0 million from $331.3 million, while operating expenses grew to $221.5 million due to higher restructuring and acquisition-related costs. For the nine-month period, net income was $277.1 million on sales of $1.58 billion. QIAGEN N.V. develops molecular diagnostics and sample preparation technologies for clinical and life science research.
